Trial Profile
An Open Label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetic/Pharmacodynamic Characteristics and Safety Following Administration of G3041 and SEVIKAR® Tablet in Healthy Adult Volunteers
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil/amlodipine (Primary)
- Indications Hypertension
- Focus Pharmacokinetics
- Sponsors Dong-A Pharmaceutical
- 21 Feb 2014 New trial record